B7-H3 CAR-T cells can eradicate OS tumor cells and thus prolong survival and bring significant clinical improvements compared to a control group and on the other hand, almost all treated metastases patients with this therapeutic application, survived longer than untreated patients (Majzner et al., 2019[70]). This evidence concerns the gene CD276 and neoplasm.